Understand the Lessons Learned from the FDA QbD Pilot Programme – Case Study Merck Serono

LONDON, February 15, 2012 /PRNewswire/ --

Senior representatives from leading pharmaceutical companies including Roche Diagnostics, Lonza, Abbott, F. Hoffman-La-Roche LTD and Novartis MIT will meet at the Pharma Qbd Forum in Berlin, Germany on 24th-25th April 2012 to share their expert knowledge on how Quality by Design can be implemented in pharmaceutical development.

One of the main points of discussion will be the findings of the Merck Serono case study and how the lessons learned from this FDA Pilot Programme can shape the way for QbD projects in Europe and abroad. This session will be led by Pascal Valax, Group Head, Biotech Process Sciences, Merck Serono SA.

Speakers include:

Dr. John R Donaubauer, Director, Scientific Affairs Development Sciences Process R&D - Abbott Dr.Richard Lakerveld, Associate - Novartis-MIT Center for Continuous Manufacturing Serj Vartanian, Head of Global Quality Systems MBB - Baxter Healthcare Corporation Dr. Gawayne Mahboubian-Jones, Program head - Excellence in Science and Design - Philip Morris International Dr.Paul Stonestreet, Global Drug Substance Project Co-ordinator, Small Molecule Technical Development - F.Hoffman-La-Roche Ltd Dr. Dirk Pamperin, VP R&D - Synthon Pharmaceuticals Dr. Alessandro Butte, Head of DSP - Lonza Sarah Mercier, Scientist USP - Crucell Holland BV Dr. John Crowley, Head of Cell Culture Development - Lonza Biologics Dr. Andreas Schneider, Vice President Life Science Alliances - Roche Diagnostics Prof. Gary Montague, Professor of Bioprocess Control - Newcastle University Dr. Mel Koch, Executive Director - CPAC Centre for Process and Analytical Control (University of Washington) Prof. Mathieu Streefland, Professor Bioprocess Engineering - Wageningen University Prof. Jose Cardoso de Menezes, Department of BioEngineering - Institute of Biotechnology & Bioengineering

Conference topics include:

Building quality earlier in the process Improving process understanding Successfully defining criticality Defining continuous verification and the expanded change protocol Lifecycle strategies for biopharmaceutical QbD Implementing continuous manufacturing with QbD to reduce production timelines Translating established development practice into QbD

To view the complete programme, speakers and topics visit http://www.pharmaqbdforum.com

For all press enquiries, email sarah.brzezicki@wtgevents.com or telephone +44(0)207-202-7727.

Link:
Understand the Lessons Learned from the FDA QbD Pilot Programme - Case Study Merck Serono

U.S. and Canadian Scientists Form a Global Alliance for Nano-Bio-Electronics in Order to Rapidly Find Solutions for …

LOS ANGELES, Feb. 13, 2012 /PRNewswire/ -- The Society for Brain Mapping and Therapeutics (SBMT) announced today that the organization will hold its 9th Annual World Congress on Brain, Spinal Cord Mapping, and Image Guided Therapy from June 2-4, 2012 in Toronto, Canada.  The world's top brain and spinal cord scientists and surgeons will converge on the Toronto Metro Convention Center to find solutions to some of the most difficult to treat neurological disorders, including traumatic brain and spinal cord injuries, Parkinson's Disease, Alzheimer's Disease, and neurological cancers. 

The 2012 World Congress of SBMT is jointly supported by the American Association of Neurological Surgeons, the Government of Canada, the University of Toronto, and MaRS innovation; it is endorsed by the International Society for Magnetic Resonance Imaging in Medicine.

The theme of this year's World Congress is "Nano-Bio-Electronics," which focuses on the integration of nanotechnology, stem cell research, and biomedical engineering, and imaging of the brain and spinal cord to make progress in the fight against neurological diseases. The aim of the Congress is to provide a multidisciplinary forum for health professionals in the fields of neurosurgery, neurology, psychiatry, radiology, neuroscience, engineering, as well as policymakers, to collaborate as a global alliance to rapidly advance treatment of neurological disorders.

"The meeting will help us kick start a unique and efficient consortium, which will unite scientists and consolidate resources in order to help us quickly come up with solutions for the devastating neurological diseases affecting millions and costing billions in the US alone," said Babak Kateb, Chairman of the Board of SBMT, President of the Brain Mapping Foundation, and Director of the National Center for Nano-Bio-Electronics (NCNBE). Dr. Kateb states, "The purpose of the Nano-Bio-Electronic alliance is to facilitate integration of nanotechnology, Stem cell and cellular therapy with medical devices and imaging. This consortium will impact global biomedical science and healthcare delivery through national and international partnerships with governments, universities, leading organizations and industries."

Among the notable participants of the 2012 World Congress includes Canadian Surgeon General Hans W. Jung, U.S. Navy Surgeon General Matthew Nathan, and Canadian Parliament Member Kirsty Duncan.  Dr. Duncan, an advocate for brain research in Canada and a global voice for neuroscience initiatives, stated "I am honored to participate in this important conference.  It is vital that we work to enhance our understanding of brain health through research and collaboration."  She added, "We must also affirm our commitment to improving the quality of life of those who live with a brain condition and of their families and informal caregivers."

Toronto was chosen for this year's meeting because of the city's strong and globally-connected network of neuroscientists, biomedical engineers, and investors in the biomedical and nanotechnology fields.   Michael Fehlings, chairman of the local organizing committee, Professor of Neurosurgery, and Director of the Neuroscience Program at the University of Toronto, said "The meeting will showcase Canadian and international neuroscience talent in a broad range of disciplines and will highlight the latest advances in imaging, molecular and cellular mechanisms, bioengineering and surgical intervention."

Parimal Nathwani, Vice President of MaRS Innovation, added, "Forums like this represent an excellent opportunity for reviewing technologies and supporting collaboration across different institutions for more effective translation and commercialization opportunity."

The 9th Annual World Congress is still accepting abstract proposals for the meeting's workshops, lectures, and presentation sessions. Abstract submission  is open now until March 15th 2012.

For the full list of 2012 speakers to register, or support of the 9th Annual World Congress of SBMT on Brain, Spinal Cord Mapping, and Image-Guided Therapy, please visit http://www.worldbrainmapping.org  or call (310) 500-6196.

Society of Brain Mapping and Therapeutics
SBMT is a non-profit society organized for the purpose of encouraging basic and clinical scientists who are interested in areas of Brain Mapping and Intra-operative Surgical planning to improve the diagnosis, treatment and rehabilitation of patients afflicted with neurological disorders.

This society promotes the public welfare and improves patient care through the translation of new technologies into life saving diagnostic and therapeutic procedures. The society is committed to excellence in education, and scientific discovery. The society achieves its mission through multi-disciplinary collaborations with government agencies, patient advocacy groups, educational institutes and private sector (industry) as well as philanthropic organization. http://www.IBMISPS.org

University of Toronto Neuroscience Program
The University Of Toronto Faculty Of Medicine established the U of T Neuroscience Program (UTNP) as a new academic program and appointed Professor Michael G. Fehlings as its first Director on September 1, 2008. The UTNP is a robust, integrated and collaborative academic program in neurosciences that leverages the unparalleled health science network at the University of Toronto, which includes U of T's many departments and institutes, health science faculties, 9 fully-affiliated research hospitals and 20 community-affiliated hospitals and clinical care sites.

MaRS Innovation
MaRS Innovation provides an integrated commercialization platform that harnesses the economic potential of the exception discovery pipeline of 16 leading academic institutions in Ontario. MaRS Innovation is a not-for-profit organization with an independent industry- led board of directors, funded through the Government of Canada's Networks of Centres of Excellence, the Province of Ontario through the Ministry of Research and Innovation, and contributions of its member institutions. Designed to enhance the commercial output of Toronto's outstanding scientific research cluster, MaRS Innovation will make a significant contribution to Canada's economic outlook and the quality of life for Canadians and others around the world. MaRS Innovation will advance commercialization through industry partnerships, licensing and company creation. The MaRS Innovation mission is to put Canada on the global innovation stage, by better connection of research with industry and strengthening Canada's competitive capacity in the knowledge based business – in short, to launch a new generation of robust high growth Canadian companies.  www.marsinnovation.com

American Association of Neurological Surgeons
The American Association of Neurological Surgeons (AANS) is the organization that speaks for all of neurosurgery. The AANS is dedicated to advancing the specialty of neurological surgery in order to promote the highest quality of patient care.  http://aans.org

Read more here:
U.S. and Canadian Scientists Form a Global Alliance for Nano-Bio-Electronics in Order to Rapidly Find Solutions for ...

UQ researchers make breakthrough in stem cell research

University of Queensland scientists have developed a world-first method for producing adult stem cells that will substantially impact patients who have a range of serious diseases.

The research is a collaborative effort involving UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN) and is led by UQ Clinical Research Centre's (UQCCR) Professor Nicholas Fisk.

It revealed a new method to create mesenchymal stem cells (MSCs), which can be used to repair bone and potentially other organs.

?We used a small molecule to induce embryonic stem cells over a 10 day period, which is much faster than other studies reported in the literature,? Professor Fisk said.

?The technique also worked on their less contentious counterparts, induced pluripotent stem cells.

?To make the pluripotent mature stem cells useful in the clinic, they have to be told what type of cell they need to become (pre-differentiated), before being administered to an injured organ, or otherwise they could form tumours.

?Because only small numbers of MSCs exist in the bone marrow and harvesting bone marrow from a healthy donor is an invasive procedure, the ability to make our own MSCs in large number in the laboratory is an exciting step in the future widespread clinical use of MSCs.

?We were able to show these new forms of stem cells exhibited all the characteristics of bone marrow stem cells and we are currently examining their bone repair capability."

AIBN Associate Professor and Co-Investigator on the project, Ernst Wolvetang said the new protocol had overcome a significant barrier in the translation of stem cell-based therapy.

?We are very excited by this research, which has brought together stem cell researchers from two of the major UQ research hubs UQCCR and AIBN,? Associate Professor Wolvetang said.

The research is published in the February edition of the STEM CELLS Translational Medicine journal.

UniQuest, The University of Queensland's main commercialisation company, invites parties interested in licensing the intellectual property relating to this discovery to contact UniQuest on 3365 4037 or lifesciences@uniquest.com.au.

Media Contact: Kirsten Rogan, Communications and Media, University of Queensland Faculty of Health Sciences, 07 3346 5308, 0412307594 or k.rogan@uq.edu.au

See the original post here:
UQ researchers make breakthrough in stem cell research

Brand Marvel Worldwide Consumer Products Corporation Update

Brand Marvel Worldwide Consumer Products Corporation (the "Company") (TSXV symbol: BMW.V) is pleased to provide updates in the Company in the following areas:

1. OEM Contracts

The Company wholly owned subsidiary, Beijing Marvel Cleansing Supplies Co. Ltd. ("BMC") recently signed a master OEM contract with a subsidiary company of Harbin Pharmaceutical Group Co. Ltd. for producing different types of wet wipes under their private label for two years. Harbin Pharmaceutical Group Co. Ltd. has two subsidiaries listed on the Shanghai Stock Exchange. Harbin Pharmaceutical Group Co., Ltd. integrates pharmaceutical manufacturing, trade, and scientific research as a whole, covering the seven industrial fields of antibiotics, chemical pharmaceutical preparations, non-prescription drugs and health-care products, traditional Chinese medicines, bioengineering medicines, animal vaccines and veterinary drugs, and pharmaceutical circulation. Its products are of more than 1,000 varieties, over 20 kinds of dosage formulations, and 7 major series, involving antibiotic bulk drugs and powder for injection, Chinese patent drugs, Chinese medicine powder for injection, and comprehensive preparations.

The first order with an amount of RMB805,400 (approximately C$129,903) was received and is now in production.

The Company is currently in negotiation with other companies to produce OEM wet wipe products for them. The Company expects to sign the final agreements in the next few weeks.

2. New Production Line

The new automatic production line of large size wet wipes was delivered to our new factory. These machinery and equipment were installed and has been set up for testing and fine tuning. The Company expects that this new automatic production line will be in normal production in around a week's time.

The total number of production lines is now increased to seven. As compared with the production capacity before, overall total production capacity will increase by 300% when running at full capacity.

3. Company Website

Due to the regulatory controls in China, the Company experienced delay in having its new website goes alive. The Company expects the new website will go alive in around one week's time. The website address is http://www.brandmarvel.com or http://www.beijingmarvel.com .

About Brand Marvel Worldwide Consumer Products Corporation ("BMW")

Beijing Marvel Cleansing Supplies Co. Ltd. ("BMC"), the wholly owned subsidiary of BMW, was incorporated as a wholly foreign owned enterprise in Beijing, China in 2003. The Company was the first to introduce wet wipes to the Chinese market and has traditionally manufactured and sold a family of non-woven wipe products for personal and household applications. BMC currently develops and produces non-woven wet wipes for both domestic and international markets under the brand name "Dreamboat". BMC produces unique wipe products in a range of sizes and containers and the current product line includes universal and generic wipes, sterilizing wipes, baby wipes, cleaning wipes and feminine hygiene wipes. BMC is a leading brand in China with a national distribution network of approximately 132 distributors and a portfolio of wipe products sold in approximately 22,000 retail outlets including Wal-Mart and Carrefour.

On behalf of the Board of Directors

"Liao Yongliang"

Liao Yongliang,

President and Director

Cautionary Statements

Statements in this press release other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, constitute forward- looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business. As a result, actual results may vary materially from those described in the forward-looking statement. Undue reliance should not be placed on forward looking statements or information. We do not expect to update forward-looking statements or information continually as conditions change, except as may be required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original post here:
Brand Marvel Worldwide Consumer Products Corporation Update

The Hertz Foundation Selects 50 Finalists for 2012-2013 Hertz Fellowship Supporting Gifted Young Leaders in Applied …

Finalists for the 2012-2013 Hertz Fellowship Below

Name               

General Field of Study        

Present or Recent School

Cheri Ackerman    

Chemistry              

University of California, Berkeley

Benjamin Altheimer   

Physical Chemistry              

Oberlin College

Scott Barenfeld            

Astronomy/Astrophysics       

University of Rochester

David Barth        

Mechanical Engineering             

University of California, Berkeley

Nicholas Boyd       

Computer Science                  

University of California, Berkeley

Allen Yuyin Chen      

Bioengineering                 

Massachusetts Institute of Technology

Allen Cheng        

Biophysics                

Harvard University

Paul Christiano             

Computer Science             

Massachusetts Institute of Technology

Sean Collins          

Chemistry                 

University of Michigan, Ann Arbor

Anna Craig          

Mechanical Engineering               

California Institute of Technology

Britni Crocker       

Biotechnology                    

Johns Hopkins University

Anjali Datta         

Electrical Engineering             

University of Texas-Austin

Matthew Edwards   

Aeronautics/Astronautics       

Princeton University

Tal Einav          

Physics                               

Rice University

George Emanuel     

Quantitative Biology, Applied Math  

University of Colorado, Boulder

Samouil Farhi   

Quantitative Biology              

University of California, Berkeley

Peter Fiflis       

Nuclear Engineering             

University of Illinois, Urbana

Aaron Gorenstein     

Computer Science               

University of Wisconsin, Madison

Olivia Hendricks    

Chemistry                         

Wellesley College

Jonathan Huggins    

Computer Science            

Columbia University

Arvind Kannan         

Chemical Engineering            

California Institute of Technology

Zachary King       

Biotechnology                  

University of California, San Diego

Philip Knodel       

Mechanical Engineering              

United States Air Force Academy

Brian Lawrence            

Mathematics                     

California Institute of Technology

Sean Lubner        

Mechanical Engineering                 

University of California, Berkeley

Christopher Madl     

Bioengineering                   

Harvard University

Max Mankin      

Chemistry                       

Harvard University

Thomas Markovich   

Physics                             

University of Houston

Daniele Monahan   

Physical Chemistry            

Yale University

Kelly Moynihan     

Biomedical Engineering               

University of Texas, Austin

Joseph Muth         

Materials Science, Engineering           

Purdue University, W. Lafayette

Marat Orazov         

Chemical Engineering             

University of California, Berkeley

Daniel Perry        

Electrical Engineering        

University of California, Los Angeles

Dan Piraner       

Structural Biology               

Purdue University, W. Lafayette

Vyas Ramanan           

Bioengineering             

Massachusetts Institute of Technology

Grant Remmen              

Physics/Astrophysics        

University of Minnesota, Minneapolis

Jonathan Russell    

Biotechnology                  

Harvard University

Jacob Sargent      

Quantitative Biology                

Massachusetts Institute of Technology

Ethan Secor           

Materials Science                  

Drake University

Hamsa Sridhar        

Applied Mathematics          

Harvard University

Jacob Steinhardt       

Computer Science              

Massachusetts Institute of Technology

Eric Stout            

Bioengineering                       

Arizona State University

Spencer Tomarken     

Physics                          

University of Chicago

James Valcourt            

Quantitative Biology, Bio-Engineering

Princeton University

Ameya Velingker       

Computer Science          

Carnegie Mellon University

Sacha Verweij       

Applied Physics                    

Stanford University

Laura Vogelaar           

Computer Science             

Georgia Institute of Technology

Yi Wang        

Mechanical Engineering                   

Massachusetts Institute of Technology

Christian Wentz       

Bioengineering                    

Massachusetts Institute of Technology

Yun Yu                

Applied Mathematics           

Imperial College London

Go here to see the original:
The Hertz Foundation Selects 50 Finalists for 2012-2013 Hertz Fellowship Supporting Gifted Young Leaders in Applied ...

US Navy eyes Aussie biofuel research

TECHNOLOGY being developed by Queensland researchers to turn agricultural waste such as bagasse from sugarcane into biofuels, has captured the interest of the US Navy, which is in Australia on a fact-finding mission on biofuels.

The US Navy intends to have a fleet of warships known as the Great Green Fleet running on biofuels by 2016 and by 2020 it plans to run half of its entire fleet on alternative fuels.

Discussing biofuel technology being developed by Queensland University of Technology (QUT) researchers was on the agenda this week when the US Navy's director for operational energy, Chris Tindal, met on Monday with QUT's Professor Sagadevan Mundree and Dr Ian O'Hara to learn more about the capabilities of QUT's Mackay Renewable Biocommodities Pilot Plant.

The meeting was followed up on Tuesday with a tour of the pilot plant in Mackay.

QUT professor Sagadevan Mun-dree said the US Navy was meeting Queensland institutions involved in research and development that could deliver the technology to industry partners, who would ultimately supply these fuels on a commercial scale.

"QUT is the only institution in Australia with the capability of dem-onstrating a diverse range of waste to biofuel technologies at the pilot scale," Professor Mundree said.

"The pilot plant has now been operational for over 14 months, so Mr Tindal is here to find out more about how the technology is progressing.

"The pilot plant is unique in that most biofuel research and development in Australia is taking place at a lab-scale level.

"However, we have the opportunity of taking biofuel technology from the concept stage to the pilot stage in a very short space of time."

Prof Mundree said the US Navy said it required 80,000 barrels of biofuel for the Green Fleet in 2016.

"We have considerable capability to develop technologies that could potentially be delivered by industry partners to satisfy a significant portion of that requirement," he said.

Researchers at the pilot plant are already working with Australian and international industry partners to develop and demonstrate technology to turn agricultural waste, such as bagasse from sugarcane, into biofuels.

"We have also partnered with a Queensland company which is developing biodiesel technologies, and we are assisting them in the demonstration of these products in the pilot plant. So far we have produced several thousand litres of biodiesel from waste agricultural oils," Prof Mundree said.

The pilot plant has been funded by the Federal Government through the National Collaborative Research Infrastructure Strategy and the Education Investment Fund, the Queensland Government's Smart State Research Facilities Fund, and QUT with the support of Mackay Sugar Ltd.

QUT's industry partners in this project include the large global agri-business Syngenta, Leaf Energy, The Biofuels Partnership and Mackay Sugar Ltd.

Minister for Agriculture, Tim Mulherin and Mackay Sugar hosted the US Navy delegation on Tuesday.

"Queensland has an opportunity to capture the interest of the US Navy with its biofuels technology development," Mr Mulherin said.

"Queensland is a big sugar producer and the state is well placed with a number of research institutions working in the biofuels area.

"There is an opportunity for Queensland to lead the way working with the US Navy in the development of next stage (demonstration-scale) commercial production of biofuels."

The US Navy also met biofuels researchers and industry leaders at the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland in Brisbane this week.

University of Queensland vice-chancellor, Professor Deborah Terry, said Mr Tindal's visit to Queensland was a credit to local researchers who were making advances in areas including new-generation 'drop-in' biofuels.

Australian Institute for Bioengineering and Nanotechnology (AIBN) business manager for systems and synthetic biology, Dr Robert Speight, said the aviation fuel research had a clear focus on "delivering real benefits to Queensland".

"Microbial fermentation is used to turn sucrose from sugarcane into advanced biofuel," he said.

Researchers are applying systems and synthetic biology to improve microbes and assess the technical and economic potential of the technology in Queensland.

Read the original:
US Navy eyes Aussie biofuel research

Researchers make breakthrough in stem cell research

The research is a collaborative effort involving UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN) and is led by UQ Clinical Research Centre's (UQCCR) Professor Nicholas Fisk.

It revealed a new method to create mesenchymal stem cells (MSCs), which can be used to repair bone and potentially other organs.

“We used a small molecule to induce embryonic stem cells over a 10 day period, which is much faster than other studies reported in the literature,” Professor Fisk said.

“The technique also worked on their less contentious counterparts, induced pluripotent stem cells.

“To make the pluripotent mature stem cells useful in the clinic, they have to be told what type of cell they need to become (pre-differentiated), before being administered to an injured organ, or otherwise they could form tumours.

“Because only small numbers of MSCs exist in the bone marrow and harvesting bone marrow from a healthy donor is an invasive procedure, the ability to make our own MSCs in large number in the laboratory is an exciting step in the future widespread clinical use of MSCs.

“We were able to show these new forms of stem cells exhibited all the characteristics of bone marrow stem cells and we are currently examining their bone repair capability."

AIBN Associate Professor and Co-Investigator on the project, Ernst Wolvetang said the new protocol had overcome a significant barrier in the translation of stem cell-based therapy.

“We are very excited by this research, which has brought together stem cell researchers from two of the major UQ research hubs UQCCR and AIBN,” Associate Professor Wolvetang said.

The research is published in the February edition of the STEM CELLS Translational Medicine journal.

Provided by University of Queensland (news : web)

See the rest here:
Researchers make breakthrough in stem cell research

Carlsberg-invested Chongqing Brewery to hire independent auditors

SHANGHAI (Feb 7): Shareholders of Chongqing Brewery voted on Tuesday to hire independent auditors to increase transparency at the Chinese beermaker after its shares plummeted more than 60 percent recently, wiping out nearly 30 billion yuan ($4.8 billion) in value.

Shareholders, however, rejected a motion to oust the chairman of China's third-biggest brewer by market capitalisation for mismanagement that led to the sharp fall in shares in December, a company official said, confirming earlier media reports.

The move to hire the auditors was proposed by Danish brewer Carlsberg A/S, which owns nearly 30 percent of the brewer.

The free-fall was triggered by a Dec. 7 statement from the company that was interpreted by the market as suggesting a new hepatitis B vaccine failed in trials conducted by its biotech arm, Chongqing Jiachen Bioengineering. The company has not made it clear subsequently if the drug did in fact fail the trials.

Dacheng Fund Management Co, which holds about 9 percent in Chongqing Brewery, called for the shareholder meeting to consider its proposal to oust the chairman, Huang Minggui, for mismanaging the disclosure of information on its drug development.

Many retail investors should be disappointed at the outcome of the ouster vote "because the chairman is widely seen as responsible for the price tumble," said Wang Yin, an analyst at Guodu Securities Co in Beijing. "The share price had been inflated by speculation, so if the drug development fails, which is likely, there's still big room for the price to fall further."

Shareholders present at Tuesday's meeting voted 97.4 percent to keep the chairman, according to an earlier report on the website of Caijing magazine.

Chongqing Brewery said last month that Carlsberg had submitted a separate proposal to hire independent accountants to audit the Chinese brewer, although it did not give a reason for the motion.

SPECULATION OVER VACCINE

Trading in Chongqing Brewery shares has been suspended pending a company announcement to the Shanghai Stock Exchange.

Analysts say the slump in the share price was more an uncoiling of the hype over the hepatitis drug that had built up over the past decade as well as a reflection of deep-rooted problems in China's stock-trading culture.

Chongqing Brewery acquired pharmaceutical firm Chongqing Jiachen Bioengineering in 1998, a year after the brewer's initial public offering in Shanghai, as part of a plan to develop a hepatitis B drug.

The business was attractive to investors as more than 100 million people in China are reported to be suffering from the illness and the deal pushed up Chongqing Brewery's share prices to exorbitant levels.

The company's stock traded above 100 times earnings before the slump, representing an exaggerated premium to its main rivals such as Tsingtao Brewery Co , which traded at 20 times in Shanghai. Despite the fall, Chongqing Brewery shares are still trading at a PE ratio of around 50 times.

Carlsberg inherited its initial stake in Chongqing Brewery through its takeover of British brewer Scottish and Newcastle and boosted its stake in the Chinese company in 2010 to become its biggest shareholder. - Reuters

Originally posted here:
Carlsberg-invested Chongqing Brewery to hire independent auditors

Industry linkage beefs up livestock nutrition

University of Queensland (UQ) research into improving livestock feed has received a boost from two Australian government-funded industry engagement schemes.

The Consulting and Research Division of UQ's main commercialisation company, UniQuest, helped an interdisciplinary team leverage an Enterprise Connect Researcher in Business (RiB) grant to secure an Australian Research Council (ARC) Linkage Grant for working with Bioproton Pty Ltd.

The team was led by Professor Kirill Alexandrov from the Institute for Molecular Bioscience (IMB) and Associate Professor Stephen Mahler from the Australian Institute for Bioengineering and Nanotechnology (AIBN).

The discovery and development of improved enzymes for feedstock supplements, and their subsequent nutritional and environmental impacts, is a key outcome of the funded research.

Associate Professor Mahler said the project had both environmental and commercial benefits.

?Growth in global food demand is placing enormous pressure on the global agricultural sector to deliver safe, efficient and environmentally sustainable food to meet demands of current and future generations," Associate Professor Mahler said.

"These grants have allowed us to investigate new approaches to accelerate the production and analysis of new generation enzymes.

?With enzyme-based supplements, farm animals excrete less phosphorus.

"A high phytate burden in soil causes eutrophication of surrounding ponds and waterways on industrial farming sites, leading to algae blooms and destruction of marine life.

?By developing livestock feed enzymes with superior characteristics that can be added economically to animal food, we can help farmers achieve more productive and environmentally sustainable farming.?

Associate Professor Mahler said that the experience of working with an industry client on a global challenge was particularly rewarding.

?As a researcher, the opportunity to move from fully funded industry research, to subsidised research through the RiB grant, and then attract an ARC Linkage project has been a valuable professional development exercise," he said.

"It has also allowed the AIBN to achieve one of its key objectives, which is to work closely with industry to bring commercial reality to scientific endeavours.?

The partnership has also achieved goals for Bioproton, a company established in Brisbane 18 years ago to manufacture and market pharmaceuticals and agribiochemicals.

?Working with the University to establish an all-in-vitro platform for protein synthesis and analysis means we can resolve a major bottleneck in protein engineering,? Bioproton director Henrik Von Hellens said.

?The world-class scientific infrastructure at The University of Queensland and close proximity to rapidly growing Asia-Pacific markets were key considerations for relocating our company's head-office, product development and manufacturing operations to Brisbane in 1993.

?This approach will deliver a novel tool for rapid engineering and biophysical analysis of proteins with much higher throughput and lower cost than presently possible.

"While this represents a competitive edge for Bioproton, there are wider implications.

?Accelerating the speed and precision with which recombinant proteins can be engineered could transform the biotechnology, ?green' chemistry and food industries.

"Developing new and novel enzymes with applications in fields other than animal nutrition is also important to our research plans.?

UniQuest Managing Director David Henderson said the project highlighted the value of an interdisciplinary approach to addressing key issues facing particular industries.

?It's another example of how university research is having a positive impact on the industries which are contributing to Australia's strong economy," he said.

"We are proud to have played a connective role in optimising the outcomes of publicly-funded scientific research and industry R&D.?

Animal nutrition has an estimated worldwide market size of US$551 million.

Although the current market is driven by protein pharmaceuticals that account for over US$160 billion in sales annually, use of recombinant proteins in the food and chemical industry is growing rapidly.

It is projected to reach market volume of $130 billion by 2012 and account for 10 per cent of sales within the chemical industry.

Media enquiries: Leanne Wyvill +61 7 3365 4037, 0409 767 199 or l.wyvill@uniquest.com.au

About UniQuest Pty Limited http://www.uniquest.com.au
Established by The University of Queensland in 1984, UniQuest is widely recognised as one of Australia's largest and most successful university commercialisation groups, benchmarking in the top tier of technology transfer worldwide. From an intellectual property portfolio of 1,500+ patents it has created over 60 companies, and since 2000 UniQuest and its start-ups have raised more than $400 million to take university technologies to market. Annual sales of products using UQ technology and licensed by UniQuest are running at $3 billion. UniQuest now commercialises innovations developed at The University of Queensland and its commercialisation partner institutions: the University of Wollongong, University of Technology Sydney, James Cook University, University of Tasmania, Mater Medical Research Institute, and Queensland Health. UniQuest also provides access to an expansive and exclusive network of independent academics to tailor a consulting or project R&D solution to meet the diverse needs of industry and government, facilitating some 500 consulting, expert opinion, testing, and contract research services each year. UniQuest is also a leading Australasian provider of international development assistance recognised for excellence in technical leadership, management and research. Working with agencies such as AusAID, NZAID, the Asian Development Bank and the World Bank, UniQuest has developed and implemented more than 400 projects in 60+ countries throughout the Pacific, South-East Asia, the Indian sub-continent and Africa.

About Bioproton Pty Ltd http://www.bioproton.com.au
Bioproton is an Australian based biotechnology company with core business in developing; manufacturing and marketing high quality feed enzyme supplements. The company was founded in 1984 in Finland. Bioproton has a global marketing and distribution network covering Africa, Asia, Europe, Russia, Middle East, North and South America. Customers can be supplied from facilities in Brisbane, Australia or Atlanta, USA.

About the Australian Institute for Bioengineering and Nanotechnology http://www.aibn.uq.edu.au
The University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) is an integrated multi-disciplinary research institute bringing together the skills of world-class researchers in the areas of bioengineering and nanotechnology. It is home to 19 research groups working at the interface of the biological, chemical and physical science to alleviate current problems in human health and environmental issues. The institute has three key areas that collectively distinguish it from other institutes in the country, namely AIBN's: research excellence; industry focus; and dynamic research environment. These characteristics focus AIBN research efforts on developing new products, processes and devices for improving human health and quality of life. In this way the institute goes beyond basic research to promote and develop the growth of innovative industries, which will benefit the Queensland and Australian economies. The AIBN proudly acknowledges the financial support of Atlantic Philanthropies, the Queensland State Government and the University of Queensland toward the construction of the A$75 million AIBN research facility.

About the Institute for Molecular Bioscience http://www.imb.uq.edu.au
The University of Queensland's Institute for Molecular Bioscience (IMB) is recognised nationally and internationally as one of Australia's leading research institutes. It was established in 2000 and houses around 400 research staff and research students with an annual budget in the order of around A$90 million. IMB researchers work on a wide range of human diseases, from early childhood developmental disorders to infectious diseases, diabetes and kidney disease. Its labs are engaged in basic or discovery-level research aimed at understanding the normal function of genes, molecules and cells in our bodies and identifying what goes wrong in disease. IMB scientists also carry out very directed research aimed at finding, testing and developing new drugs to treat human diseases. The Institute has major research programs in pain, cancer and infection.

Here is the original post:
Industry linkage beefs up livestock nutrition

A marketable major

For freshman Jeff To, the heavy workload he will take as a biology major pays off with job security later on.

To, a pre-dentistry student, will have gone to school for more than two decades before he enters the job market. However, given the continuing need for dentists, his education will guarantee a stable career after graduation.

Like many UW students, To chose a major not based on his passion but based on the needs of today’s job market.

“Security definitely plays a big piece in my major choice and also just peace of mind,” he said. “I don’t mind putting in a bunch of effort and working really hard now so later on my future family can benefit.”

With UW students now paying for 69 percent of their education, as opposed to 58 percent in 2009, Patsy Wosepka, director of Undergraduate Academic Affairs Advising, said looming debt forces some undergraduates to worry about the practicality of their majors in the job market.

The sensibleness of bioengineering is what drew junior Krisla Nguyen toward the major. As a freshman at the UW, she said she didn’t know what she wanted to major in.

“I knew I wanted to go to med school, but I didn’t know the path to take,” Nguyen said. “So when I found bioengineering, I picked that because it was practical.”

Outside the classroom

With only about 150 people in the major, bioengineering offers many opportunities for hands-on experience, something that Wosepka said is vital when looking for a job.

“People are getting more concerned about what the practical application of the degree [is],” she said. “But I think also, in this tough economic time, it is more necessary to get that internship experience — that experience actually out there doing what it is you want to do.”

Wosepka said she would argue that major is becoming less important to the job market while the need for experience is growing constantly.

“Experiences outside the classroom are as important, maybe more important, than the actual major,” Wosepka said. “Having the skills you need to hit the ground running when you start a job is going to become more and more important.”

As a freshman, To is getting a head start on his experience. This summer, he has an internship set up with his family dentist.

“It’s about the baby steps,” he said.

Nguyen plans on going to medical school after college, so she said she takes advantage of opportunities that will put her ahead of the competition.

Her work in a research lab on campus gives her that edge. Beginning as a volunteer during her sophomore year, she now gets paid for her research and plans on using the lab in her senior capstone project.

If medical school doesn’t work out, Nguyen said that bioengineering offers more practical careers in the job market “instead of just regular biology.”

“It’s a good major because it will prepare you for the industry and prepare you for research as well as preparing you for medical school,” she said. “It’s a budding field, and I know that a lot of people have been really successful in those areas.”

Passion or practicality

For Nguyen, bioengineering is more than just a job guarantee; it’s something she is passionate about. Such passion will allow students to succeed both in school and careers, Wosepka said.

“It’s interesting looking at a student’s transcript because you see where they’re just beating their head against the wall, but then you look and there’s 4.0s in other classes because that’s just what they love to learn,” she said. “It would be a mistake for that student to continue in the wrong direction.”

To, however, takes a different approach looking at his major.

“Everyone always tells you to find a job you’re going to love and stick to it,” he said, “but I’ve always been the type of guy that, whenever I get into something, I just have tunnel vision, and I don’t want to do that with my job. I feel like dentistry is a job that I could just do. It’s not something I will be incredibly passionate about, but it’s not something I’ll hate.”

In the 2009-10 graduation survey, the UW Career Center found dentistry is one of the high-paying jobs, with an average salary of over $100,000. Also on the higher end were careers in nursing, engineering, and computer science.

Other majors, especially social science–based ones, have a wider range of salaries and offer less job security to graduates. However, it is important not to discount those majors, said Wosepka. Such majors offer skill sets applicable to the job market.

“Being able to communicate well, being able to work in teams and being able to find answers long after you leave here are all things employers look at,” she said.

Advisers at the Undergraduate Academic Affairs Advising agree that the major itself is not necessarily as important as the skills you learn while at the UW.

“Your college education prepares you for multiple opportunities,” adviser Donna Sharpe said. “You don’t necessarily have to major in something you want to work in.”

Because most majors aren’t career-specific, Sharpe emphasized that a student’s major doesn’t always equate to his or her future career. In the average lifetime, she said, a graduate will have five to seven careers which usually don’t relate directly to their major.

Despite this, many undergraduate students still worry about the practicality of their major beyond college.

“Students really intensely need to know they are going to be able to support themselves with that degree,” Wosepka said. “They are coming in feeling that need to know more quickly and to be able to get settled into something.”

The ability to settle down is especially important to To, whose parents are immigrants to the United States. As a first-generation student, he said his life was often unstable and that is what motivated him to pursue dentistry. He looks at his biology major as a path to this career.

“I moved around a lot, but my parents always emphasized that this wouldn’t have to happen if we made more money, so that really was a driving factor,” he said. “If I can decently support my family and be able to spend a lot of time with my kids, I feel like that would be more than enough to make me happy.”

Reach reporter Jillian Stampher at news@dailyuw.com.

Excerpt from:
A marketable major

US Navy here to talk biofuels

Vice-Chancellor Professor Deborah Terry discussed UQ's suite of biofuels research with the US Navy's Director for Operational Energy, Chris Tindal, and the AIBN director, Professor Peter Gray (right).

THE United States Navy's Director for Operational Energy today visited The University of Queensland for discussions on UQ's world-leading biofuels research.

As the US Department of Defense actively pursues ambitious targets and new ?green? fuel sources for its energy requirements, the US Navy's Chris Tindal met biofuels researchers and industry leaders at the Australian Institute for Bioengineering and Nanotechnology at UQ in Brisbane.

Vice-Chancellor Professor Deborah Terry welcomed Mr Tindal, saying his visit to UQ was a credit to UQ researchers who are making advances in areas including new-generation ?drop-in? biofuels.

?Drop-in biofuels are physically or chemically identical to traditional fossil fuels, and suit existing distribution networks and engines,? she said. ?Much of our leading-edge research and development is focused in this area.

?Teams of scientists, engineers and economists at UQ are expanding knowledge and technology in biofuels that are based on a range of feedstocks, including sugar cane, algae, eucalypts and the oily seeds of a tree known as pongamia.

?Their work is enhanced by links with international and Australian partners and collaborators, including leaders in aviation, air travel and energy; innovative biofuels manufacturers; feedstock producers; and renowned research institutions.?

Both the Queensland and Australian governments have provided funding to foster UQ biofuels research, and UQ is establishing a multidisciplinary UQ Biofuels Initiative aimed at accelerating biofuels production in Australia

Professor Chris Greig, director of UQ's Energy Initiative, said the Queensland Sustainable Aviation Fuel Initiative was a key part of the UQ Biofuels Initiative. With significant backing from the Queensland Smart State program, this research was being undertaken at the Australian Institute for Bioengineering and Nanotechnology at UQ.

?This program is a collaboration between the AIBN, the Institute for Molecular Bioscience, the Queensland Alliance for Agricultural and Food Innovation, the Centre for Integrative Legume Research, James Cook University, Boeing, Virgin Australia, IOR Energy, Amyris and Mackay Sugar,? Professor Greig said.

AIBN Systems and Synthetic Biology Group business manager Dr Robert Speight said the aviation fuel research had a clear focus on ?delivering real benefits to Queensland?.

?Microbial fermentation is used to turn sucrose from sugarcane into advanced biofuel,? Dr Speight said. ?AIBN researchers are applying systems and synthetic biology to improve the microbes as well as assessing the technical and economic potential of applying the technology in Queensland.

?The overall aim of this multi-stage program is to enable commercial manufacture of biofuel from Queensland sugarcane, supply the aviation fuel market in Australasia and help seed a strong and sustainable domestic advanced biofuel industry.?

The next step for the initiative is to evaluate commercial viability and continue to enhance the fermentation process, Dr Speight said.

The Royal Australian Navy's Environment Manager, Commander Steve Cole, accompanied Mr Tindal on his visit to UQ today.

The US Navy has made a commitment that by 2020, at least half of all Navy energy, afloat and ashore, will come from renewable sources.

In his State of the Union address two weeks ago, President Barack Obama outlined the Navy's energy security goals, including its commitment to consume one gigawatt of new, renewable energy on its naval installations.

"I'm proud to announce that the Department of Defense, the world's largest consumer of energy, will make one of the largest commitments to clean energy in history - with the Navy purchasing enough capacity to power a quarter of a million homes a year," the President said.

Media:
Dr Rob Speight, AIBN, ph 0451 181 664
Erik de Wit, AIBN Communications, ph 07 3346 3962
Fiona Cameron, UQ Office of Marketing and Communications, ph 07 3846 7086
Jan King, UQ Office of Marketing and Communications, ph 0413 601 248

Read the original here:
US Navy here to talk biofuels

India gets her own stem cell hosptial

This was an interesting, albeit expensive tidbit I saw today...India is apparently getting a INR 90 crore hospital, dedicated solely to stem cell treatments. At the outset, it appears to be a cool idea. The plans call for the Government to spend all of the money required to build the hospital, with an initial investment of  INR 30 crores in the first year.

The partner, is Giostar, or Global Institute of Stem-cell Therapy and Research, based in San Diego. Not much information is available, but it appears that quite a number of the founders are of Indian origin.

IMO, the plan itself seems to capitalize on the difference between the dollar and the rupee, the growth in India, its large population with a variety of disease presentations (which yours truly discovered by doing some ear to the ground empirical research in 2006) and of course, looser regulatory infrastructure on the part of the Government. Mind you, this is just my guess work.

However you look at it, this appears to be a good idea and a win-win situation for everyone involved. Of course, given the obscurity of Giostar (at least in my run of the mill attempt at learning more about them), the Government is taking a bigger risk right now. Should it pay off though, Surat and consequentially India will become quite the stem cell research hub though.

The Regulatory Atmosphere: For a young India, unable to grasp its own might, and lacking the leadership, this just might be the break. After all, India has fallen behind and stayed behind China in almost every way. However, unlike China, hopefully the regulatory environment will mature faster than the various "stem cell" hospitals that are about to proliferate.

Unless you have been hiding in some biotech cave, China recently started clawing back on all the fake and ineffective stem cell studies that have showed up there. As of now, most countries have a reactionary philosophy towards regulations. The recent deaths due to contaminated drugs in Pakistan can only serve as a grim reminder!







References:

1. http://articles.timesofindia.indiatimes.com/2012-01-30/surat/31005286_1_cell-technology-sickle-cell-new-civil-hospital-campus

2. http://www.giostar.net/

3. http://wpclipart.com/

4. http://www.freeusandworldmaps.com/html/Countries/Asia%20Countries/IndiaPrint.html

Source:
http://chaaraka.blogspot.com/feeds/posts/default

Plandai Biotechnology, Inc. Announces Appointment of World-Renowned Physicist to Chair Plandai Scientific Board

SEATTLE, WA--(Marketwire -01/30/12)- Plandaí Biotechnology, Inc.
(OTC.BB:
PLPL.OB -
News) Chief Executive Officer, Roger Duffield, today
announced that Dr. Tom Matula has accepted the position
of Chairman of the Scientific Board for Plandaí Biotechnology,
Inc., effective immediately.

Dr. Matula is a world-renowned scientist and entrepreneur with
expertise in medical and industrial applications of ultrasound.
He is the author of over 40 peer-reviewed publications and has
several patents in the medical devices landscape. Dr. Matula is
a past winner of the Department of Defense Young Scientist
Award and was also awarded the Presidential Early Career Award,
the highest honor bestowed by the United States government on
science and engineering professionals in the early stages of
their careers. He has advised members of congress on energy
issues, and helps organize panels on technology transfer out of
universities.

Dr. Matula received his PhD. in Physics from Washington State
University. He currently serves as Affiliate Associate
Professor, Bioengineering and Electrical Engineering with the
University of
Washington, is the Director of the Center for Industrial
and Medical Ultrasound and the Director of the Center for
Ultrasound-based Molecular Imaging and Therapy, both with the
University of Washington. Dr. Matula also serves as Principal
Physicist with the Applied Physics Laboratory at the University
of Washington.

Dr. Matula is a co-inventor of Plandaí Biotechnology's proprietary
technology that extracts a high level of bio-available
compounds from organic matter including green tea leaves and
most other organic materials. Various tests have been conducted
over the past ten years using this technology that generates
functional chemical compounds possessing nutritive properties
that act effectively as preventive agents in the healthcare
field. Polyphenols from green tea are an excellent source of
antioxidant and anti-carcinogenic substances. Dr.Matula has
been instrumental in bringing this technology to market through
Plandaí Biotechnology.

Mr. Duffield commented, "Plandaí is delighted that Dr. Matula
has accepted the chair position as we have been working
together on the science behind our company for over 10 years.
As a scientist, he brings a wealth of experience and insight as
we transition from research into market-ready products. Plandaí
Biotechnology intends to continue adding highly qualified and
experienced professionals to our Scientific Advisory Board. Dr.
Matula's leadership as the Chairman of our Scientific Board
demonstrates the acceptance within the scientific community of
our technology."

Additional information on Dr. Matula's background can be found
at:
http://www.apl.washington.edu/people/profile.php?last=Matula&first=Tom.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc., through its recent acquisition of
Global Energy Solutions, Ltd. and its subsidiaries, focuses on
the farming of whole fruits, vegetables and live plant material
and the production of proprietary functional foods and
botanical extracts for the health and wellness industry. Its
principal holdings consist of land, farms and infrastructure in
South Africa.

Go here to read the rest:
Plandai Biotechnology, Inc. Announces Appointment of World-Renowned Physicist to Chair Plandai Scientific Board

Need muscle for a tough spot? Turn to fat stem cells

ScienceDaily (Jan. 30, 2012) — Stem cells derived from fat have a surprising trick up their sleeves: Encouraged to develop on a stiff surface, they undergo a remarkable transformation toward becoming mature muscle cells. The new research appears in the journal Biomaterials. The new cells remain intact and fused together even when transferred to an extremely stiff, bone-like surface, which has University of California, San Diego bioengineering professor Adam Engler and colleagues intrigued. These cells, they suggest, could hint at new therapeutic possibilities for muscular dystrophy.

In diseases like muscular dystrophy or a heart attack, “muscle begins to die and undergoes its normal wounding processes,” said Engler, a bioengineering professor at the Jacobs School of Engineering at UC San Diego. “This damaged tissue is fundamentally different from a mechanical perspective” than healthy tissue.

Transplanted stem cells might be able to replace and repair diseased muscle, but up to this point the transplants haven’t been very successful in muscular dystrophy patients, he noted. The cells tend to clump into hard nodules as they struggle to adapt to their new environment of thickened and damaged tissue.

Engler, postdoctoral scholar Yu Suk Choi and the rest of the team think their fat-derived stem cells might have a better chance for this kind of therapy, since the cells seem to thrive on a stiff and unyielding surface that mimics the damaged tissue found in people with MD.

In their study in the journal Biomaterials, the researchers compared the development of bone marrow stem cells and fat-derived stem cells grown on surfaces of varying stiffness, ranging from the softness of brain tissue to the hardness of bone.

Cells from the fat lineage were 40 to 50 times better than their bone marrow counterparts at displaying the proper proteins involved in becoming muscle. These proteins are also more likely to “turn on” in the correct sequence in the fat-derived cells, Engler said.

Subtle differences in how these two types of cells interact with their environment are critical to their development, the scientists suggest. The fat-derived cells seem to sense their “niche” on the surfaces more completely and quickly than marrow-derived cells. “They are actively feeling their environment soon, which allows them to interpret the signals from the interaction of cell and environment that guide development,” Choi explained.

Perhaps most surprisingly, muscle cells grown from the fat stem cells fused together, forming myotubes to a degree never previously observed. Myotubes are a critical step in muscle development, and it’s a step forward that Engler and colleagues hadn’t seen before in the lab.

The fused cells stayed fused when they were transferred to a very stiff surface. “These programmed cells are mature enough so that they don’t respond the environmental cues” in the new environment that might cause them to split apart, Engler says.

Engler and colleagues will now test how these new fused cells perform in mice with a version of muscular dystrophy. The cells survive in an environment of stiff tissue, but Engler cautions that there are other aspects of diseased tissue such as its shape and chemical composition to consider. “From the perspective of translating this into a clinically viable therapy, we want to know what components of the environment provide the most important cues for these cells,” he said.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of California - San Diego.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Jennifer L. Young, Adam J. Engler. Hydrogels with time-dependent material properties enhance cardiomyocyte differentiation in vitro. Biomaterials, 2011; 32 (4): 1002 DOI: 10.1016/j.biomaterials.2010.10.020

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Excerpt from:
Need muscle for a tough spot? Turn to fat stem cells

Calling BS on the link between tax increases and medical device innovation…

I know I haven't posted here in months. Things have been quite busy and I am unable to write as much as I would like. That said, I wanted to leave 2011 with a "I told you so" post, so that I can come back and harp on this later.

Is money the problem with innovation?

How does more money equate innovation? Is it the same expectation as throwing many monkeys in a room with a bunch of keyboards and expect them to produce great literature? It probably is. Has it ever worked? Maybe you will get a couplet out of it, but can you expect a sonnet?
Is laying people off the most innovative solution to increased taxes?

I am not at all for increasing taxes. However, how else would you expect incomes to come in to pay to allow more Americans to access health. One "large" organization is claiming that it will lay off 1000 employees to pay for the taxes. Now, is this really the way to innovation? They can't cut other costs? 
When costs increase, do you skip meals, or skip the movie outings? Every lay-off is grounds to believe that the CEO and management has probably failed TWICE. Why twice? First, they probably did some very inefficient hiring, and secondly they chafe responsibility. 
Well, you have to ask yourself this. Why did they hire a 1000 employees too many? First of all, it never happens to be that much, and secondly, yes, it happens - employee functions disappear and such, but more or less, this is just because the "management" in most of these organizations is an old boys (and girls) club and they want to get rid of well meaning employees, rather than cut from a management.
Shouldn't a performance failure directly mean management failure?

The Cisco Example

Look at the CEO of Cisco. The company was in dire straits in 2011 directly because of his narrow mindset, heck, his inability to produce results. Why mince words? Yet, he got to lay off thousands of jobs and keep his. Ask yourself...
The HP Example

HP had it going for a while. They bought worthless companies, hired duds and kept sending them off with golden parachutes. When things got hot though, what was their solution? Well, they brought Meg Whitman, of the "I took the eBay stock and rubbed it in kaka" fame, and "I hired an illegal immigrant and decided to run for a Governor on behalf of the people opposed to that" fame as well in as the CEO. Here is the kicker - she was on the board that made all the poor decisions in the first place!!!!
What are the real roadblocks to innovation?

A 2.3% tax increase is not the reason why innovation in medical device design is going to retroactively die, as John Kartch and Stephen MacMillan would like to misinform you. Let us look at some real issues:
1. The mid-life crisis - monkey see, monkey want

There were some innovations in the industry, and then for the most part, they tend to poke out their head out of the vast desert stands of the medical device industry every so often. Why so? 
This was a problem in 2007, it is very much a problem even now. One stent succeeds marginally, of course the success is called phenomenal at first, and everyone wants to build a stent company. A catheter company succeeds and of course everyone wants to build...well, you get the point, monkey see, monkey want, monkey try, body not agree, monkey blames taxes, the FDA, the Mayan calendar, everything except self...

There is no attempt at real innovation here, just a need to create copycats. You can see it in the companies, their names and even their job advertisements - Wanted: Someone who has designed 233 catheters and wishes to design their 234th; slavery a must, peanuts optional...

Innovative, no?

2. Crash and Burn - VC style..


The Venture Capitalists who got there with almost nothing but sheer luck and no nothing about devices have their own plan. Under-fund a company on crappy me-too ideas, going after diseases and devices just before they get to the "also-ran" point, and demand quick results that lead you to King Solomon's mines...

The companies that are lucky enough to get this money go after said diseases and devices in a rushed manner, fail and then give the whole thing a bad name, making it bad for anyone trying to go after this a second time around.

And then of course the VCs bandy together and blame regulations for the failures of their minion companies...

3. Taking the wrong risks and avoiding the right ones


Innovation is risky business. By treading the familiar path, you will never innovate. You have to branch off, go against the flow and all that to actually change the way something happens. You really, really cannot do anything but micro-innovate your way to success.

The easy way out, is to blame Obama, the tax man, the regulations, heck even the Mayans and their calendars...and this, is what I am calling BS on...

Source:
http://chaaraka.blogspot.com/feeds/posts/default

Stanford’s Stephen Quake, Bioengineer – Video

18-11-2011 11:30 Stanford's Stephen Quake, PhD, a professor of bioengineering and applied physics, discusses his work to create a rapid/inexpensive genome sequencer and what he learned looking at his own genome. He also discusses his other work, including a non-invasive prenatal test for Down Syndrome that is in clinical trials now and work on circuits built on biological systems rather than electronics.

Link:
Stanford's Stephen Quake, Bioengineer - Video

White House Awards UC San Diego Bioengineering Professor Shu Chien National Medal of Science – Video

President Barack Obama today named University of California, San Diego bioengineering professor Shu Chien one of the seven eminent researchers to receive the National Medal of Science, the highest honor bestowed by the United States government on scientists and engineers. Chien is the only engineer among the seven medalists.

Go here to read the rest:
White House Awards UC San Diego Bioengineering Professor Shu Chien National Medal of Science - Video

PhD Research in Belgium (Bioengineering at the University of Leuven) – Video

Aaron New is doing research at the University of Leuven (KULeuven) in Belgium in order to obtain a PhD in Bioengineering. In this video he talks about why he decided to come to Belgium and gives advice to other researchers who are considering coming to Europe to do research.

See more here:
PhD Research in Belgium (Bioengineering at the University of Leuven) - Video